←back to thread

234 points Eumenes | 8 comments | | HN request time: 0.984s | source | bottom
1. therein ◴[] No.42199515[source]
I like how they aren't saying Semaglutide in the title in an attempt to perhaps keep it from immediate scrutiny.
replies(3): >>42199537 #>>42199577 #>>42199612 #
2. neom ◴[] No.42199537[source]
https://www.fda.gov/drugs/postmarket-drug-safety-information... Same thing??
replies(2): >>42199588 #>>42199590 #
3. rzzzt ◴[] No.42199577[source]
The first link goes to the study and it does mention the ingredient: https://www.sciencedirect.com/science/article/pii/S2452302X2...
replies(1): >>42199584 #
4. therein ◴[] No.42199584[source]
I am talking about UAlberta's title specifically.
replies(1): >>42199637 #
5. therein ◴[] No.42199588[source]
> Unapproved GLP-1 Drugs Used for Weight Loss Yeah that would be perfect. But editorializing it to the point of calling it `weight loss drug`, just feels like it is begging for the reaction of "oh yet another weight loss drug".
6. TylerE ◴[] No.42199590[source]
No. That’s talking about the compounded versions (NOT in an auto pen) that were temporarily allowed due to shortages, but whose authorization has since been revoked.
7. skeaker ◴[] No.42199612[source]
More likely because the average reader won't know what that is versus the current title which succinctly summarizes it.
8. rzzzt ◴[] No.42199637{3}[source]
"Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice" was also written by UoA researchers. I don't see anything nefarious in the choice of the title for the news blurb.